Merozan Adverse Reactions

Meropenem (Merozan) is generally well tolerated and adverse effects rarely require discontinuation of the treatment.
Serious adverse events are rare. Most of the following adverse events have been reported in less than 1% of the patients: Local intravenous injection site reactions: Inflammation, thrombophlebitis, pain at the site of injection.
Systemic allergic reactions: Rarely, systemic allergic reactions (hypersensitivity) may occur following administration of Meropenem (Merozan). These reactions may include angioedema and manifestations of anaphylaxis.
Skin reactions: Rash, pruritus, urticaria. Rarely, severe skin reactions such as erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis have been observed.
Gastrointestinal tract: Abdominal pain, nausea, vomiting, diarrhoea.
Blood: thrombocythaemia, eosinophilia, thrombocytopenia, leucopenia and neutropenia (including very rare cases of agranulocytosis). A positive direct or indirect Coombs test may develop in some patients. There have been also reports of reduction in partial thromboplastin time.
Liver function: Increase in serum levels of bilirubin, transaminases, alkaline phosphatase and lactic dehydrogenase, alone or in combination, have been reported;
Central nervous system: Headache, paraesthesia. Convulsions have been rarely reported but a causal link with meropenem treatment has not been established;
Other: Oral and vaginal candidiasis.